Ardea Biosciences, Inc.
1009 Oak Hill Road
Suite 201
Lafayette,
CA 94549
Phone: 925-906-5331
Web Site: http://www.ardeabiosciences.com
| Ardea Biosciences, Inc. engages in the research and development of pharmaceutical products for the treatment of HIV, cancer, and inflammatory diseases in the United States. Its development programs include 800 Series Program, phase I clinical study, for the discovery of non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the potential treatment of HIV; 900 Series Program in preclinical development stage, which is also directed towards the discovery of NNRTIs for the treatment of HIV and uses a chemical class that is distinct from the chemical class being investigated in the 800 Series Program; 100 Series Program in preclinical development stage, directed toward the discovery of small-molecule kinase inhibitors for the potential treatment of cancer and inflammation. The company is based in Carlsbad, California. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Dr. Barry D. Quart , 50
Chief Exec. Officer, Pres
|
$
250.00K |
N/A |
Mr. Denis Hickey , 63
Chief Financial Officer and Principal Accounting Officer
|
N/A
|
N/A |
Ms. Kimberly J. Manhard , 48
Sr. VP of Operations and Regulatory Affairs
|
$
50.00K |
N/A |
Dr. Colin E. Rowlings Ph.d., 44
Sr. VP of Pharmaceutical Sciences
|
N/A
|
N/A |
Mr. Christopher W. Krueger J.D., MBA., 40
Chief Bus. Officer and Sr. VP
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-06
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
Profile
